Previous 10 | Next 10 |
Gainers: Dova Pharmaceuticals (NASDAQ: DOVA ) +38% . USA Technologies ( OTC:USAT ) +28% . Farmmi (NASDAQ: FAMI ) +24% . Thor Industries (NYSE: THO ) +21% . GTT Communications (NYSE: GTT ) +15% . Patrick Industries (NASDAQ: PATK ) +12% . Seattle Genetics (NASDAQ: SGEN ) +10% . ...
Gainers: Aclaris Therapeutics (NASDAQ: ACRS ) +68% . Avadel Pharmaceuticals plc (NASDAQ: AVDL ) +20% . BioCardia ( OTCQB:BCDA ) +15% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +14% . Earthstone Energy (NYSE: ESTE ) +14% . Pier 1 Imports (NYSE: PIR ) +15% . SunPower Corporation (...
Cellular Biomedicine Group (NASDAQ: CBMG ) initiated with Buy rating and $19 (28% upside) price target at BTIG Research. More news on: Cellular Biomedicine Group, Inc., Lexaria Bioscience Corp., Orchard Therapeutics plc, Healthcare stocks news, , Stocks on the move, Read more ...
Based on the recommendation from the independent Data Safety Monitoring Board, the Phase 3 clinical tria l evaluating BioCardia's ( OTCQB:BCDA -6.3% ) CardiAMP cell therapy for the treatment of heart failure will continue as planned after no safety signals were reported. More news on:...
SAN CARLOS, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data...
BioCardia ( OTCQB:BCDA ): Q2 GAAP EPS of -$0.77. More news on: BioCardia, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN CARLOS, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter 2019 and fil...
SAN CARLOS, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the European Patent Office has issued the Company Patent No: 3063172 for ...
SAN CARLOS, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NasdaqCM: BCDA, BCDAW), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the closing of its previously announced public offering of 1,666,667 units ...
Ultra-thinly traded nano cap BioCardia ( OTCQB:BCDA ) has rebounded from early pressure on increased volume, albeit on turnover of only 68K shares, in reaction to its public offering of ~1.7M units at $6 per unit. More news on: BioCardia, Inc., Healthcare stocks news, Stocks on the move,...
News, Short Squeeze, Breakout and More Instantly...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therap...
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: 12,036,371 ti...
SUNNYVALE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States Patent Office has granted Patent No: ...